Zometa

Osteoporosis, Chemotherapy, Osteoporosis + 10 more
Treatment
20 Active Studies for Zometa

What is Zometa

Zoledronic acidThe Generic name of this drug
Treatment SummaryZoledronic acid (also known as CGP 42'446) is a medication used to treat and prevent a variety of bone-related conditions, including osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. It was first approved by the FDA in 2001 and is classified as a third-generation, nitrogen-containing bisphosphonate, similar to ibandronic acid, minodronic acid, and risedronic acid.
Zometais the brand name
image of different drug pills on a surface
Zometa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zometa
Zoledronic acid
2001
53

Effectiveness

How Zometa Affects PatientsZoledronic acid is a medication used to prevent bone loss that works by blocking the action of osteoclasts. It has a wide range of therapeutic benefits and does not typically cause severe side effects from an overdose. However, it can cause issues such as electrolyte deficiencies, renal impairment, jaw necrosis, fractures, lung constriction, liver damage, low calcium levels, and harm to unborn babies. Patients should be aware of these risks before taking the medication.
How Zometa works in the bodyBisphosphonates work in the body by attaching to bone, which prevents the osteoclasts from breaking down the bone and causes them to detach. This stops the bone from being broken down and resorbed. In addition, nitrogen-containing bisphosphonates like zoledronate also block the mevalonate pathway, which is necessary for certain proteins to function and survive. This causes them to die off, which helps to stop the spread of tumor cells. Finally, zoledronate activates caspases, which also contributes to cell death.

When to interrupt dosage

The proposed amount of Zometa is contingent upon the diagnosed ailment, including Bone Mineral Density, Paget’s Disease and Osteoporosis caused by glucocorticoid. The amount of dosage is subject to the administration procedure featured in the table below.
Condition
Dosage
Administration
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Bone Metastases
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Malignant Neoplasms
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Paget’s Disease
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Chemotherapy
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Multiple Myeloma
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Glucocorticoids
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Disease
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Postmenopause
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteitis Deformans
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Zometa Contraindications
Condition
Risk Level
Notes
Renal Insufficiency, Chronic
Do Not Combine
Hypocalcemia
Do Not Combine
Acute Kidney Injury
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Zoledronic Acid may interact with Pulse Frequency
There are 10 known major drug interactions with Zometa.
Common Zometa Drug Interactions
Drug Name
Risk Level
Description
Alendronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.
Clodronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Clodronic acid.
Etidronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Etidronic acid.
Ibandronate
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate.
Incadronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Incadronic acid.
Zometa Toxicity & Overdose RiskOverdosing on a drug may cause reduced kidney function, low levels of calcium, phosphorus, and magnesium in the blood. If this occurs, intravenous treatment with the lacking ions is necessary.
image of a doctor in a lab doing drug, clinical research

Zometa Novel Uses: Which Conditions Have a Clinical Trial Featuring Zometa?

320 active clinical trials are assessing the efficacy of Zometa in providing relief for Osteoporosis, Malignant Neoplasms and Solid Tumors.
Condition
Clinical Trials
Trial Phases
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Osteoporosis
3 Actively Recruiting
Not Applicable
Bone Metastases
7 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3
Disease
3 Actively Recruiting
Early Phase 1, Not Applicable
Osteoporosis
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Chemotherapy
3 Actively Recruiting
Phase 1, Phase 3, Not Applicable
Postmenopause
8 Actively Recruiting
Phase 2, Not Applicable, Phase 1
Glucocorticoids
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting
Osteoporosis
34 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3
Osteoporosis
0 Actively Recruiting
Osteitis Deformans
0 Actively Recruiting

Zometa Reviews: What are patients saying about Zometa?

5Patient Review
10/12/2016
Zometa for Lesions in the Bone of the Disease Multiple Myeloma
I've had this treatment three times now and have yet to experience any negative side-effects. The process is spread out over 30 minutes, which I appreciate.
5Patient Review
6/24/2014
Zometa for Cancer that has Spread To the Bone From Solid Tumors
I've been getting monthly IV infusions of Zometa for 18 months now, and I haven't had any noticeable side effects other than a bit of fatigue when I first started taking it (but that might have also been because I was starting other medications at the same time). It's definitely helped with my pain levels too - I'm still able to exercise 4 km. every day on the treadmill! All in all, I'm really happy with this medication.
5Patient Review
1/11/2018
Zometa for Lesions in the Bone of the Disease Multiple Myeloma
Before treatment, I could barely walk due to the compression fractures in my spine. A year later and I'm in remission thanks to incredibly effective drugs and therapies. Nowadays, you would never know that I ever had a problem if I didn't tell you.
4.3Patient Review
8/29/2020
Zometa for Osteoporosis caused by Anti-Androgen Drugs
I've been on this medication for six months now, and I have to say that it's helped me a lot. I was worried about bone loss due to the anti-hormone drug I take, but this has really reduced my risk. I still get some joint pain and fatigue, but it's nothing compared to what it used to be.
4Patient Review
5/18/2022
Zometa for prevention of skeletal related events in multiple myeloma
I had some pain after my first infusion, which was to be expected. What I didn't expect was how long it would last! Make sure to take Tylenol before and after your treatment.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zometa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Zometa chemotherapy?

"Zoledronic acid is not a cancer chemotherapy, however it can be used to treat bone disease in patients who have cancer. Zoledronic acid is in a class of medications called bisphosphonates."

Answered by AI

What does Zometa do to your body?

"This medication works by reducing the amount of calcium that is released from the bones into the bloodstream. It also slows down the rate at which cancer cells break down bones, which helps to prevent fractures."

Answered by AI

What are the long term side effects of Zometa?

"Some possible symptoms of a brain tumor could include changes in vision, decreased frequency of urination, increased tearing, heavy feeling in the jaw, and increased blood pressure."

Answered by AI

Is Zometa cancer treatment?

"The drug Zometa is approved by the FDA to treat multiple myeloma and bone metastases from solid tumors. It is typically used in conjunction with other standard treatments for cancer, such as chemotherapy, radiation therapy, and hormone therapy. Zometa is also sometimes used to treat bone metastases specifically from prostate cancer."

Answered by AI

Clinical Trials for Zometa

Have you considered Zometa clinical trials? We made a collection of clinical trials featuring Zometa, we think they might fit your search criteria.
Have you considered Zometa clinical trials? We made a collection of clinical trials featuring Zometa, we think they might fit your search criteria.
Have you considered Zometa clinical trials? We made a collection of clinical trials featuring Zometa, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top